Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition

This publication has 15 references indexed in Scilit:

• Fibroblast growth factor receptors as treatment targets in clinical oncology
  Nature Reviews Clinical Oncology, 2018
• Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
  Ophthalmology, 2017
• Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors
  JAMA Oncology, 2017
• Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis
  Oncotarget, 2016
• Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients
  Medicine, 2016
• Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data
  Journal of Ophthalmology, 2014
• Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
  Cancer Treatment Reviews, 2013
• The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate
  Neoplasia, 2002
• Fibroblast Growth Factor (FGF) Soluble Receptor 1 Acts as a Natural Inhibitor of FGF2 Neurotrophic Activity during Retinal Degeneration
  Molecular Biology of the Cell, 1998
• Baseline and Early Natural History Report
  Archives of Ophthalmology (1950), 1993